Adverse reactions to the first and second doses of Pfizer-BioNTech COVID-19 vaccine among healthcare workers
Author:
Publisher
Elsevier BV
Subject
Infectious Diseases,Pharmacology (medical),Microbiology (medical)
Reference17 articles.
1. Reactogenicity following receipt of mRNA-based COVID-19 vaccines;Chapin-Bardales;JAMA,2021
2. Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination, March-June 2021, England;Powell;Euro Surveill,2021
3. Early solicited adverse events following the BNT162b2 mRNA vaccination, a population survey from Saudi Arabia;Almohaya;Prev Med Rep,2021
4. Adverse reactions following the first dose of ChAdOx1 nCoV-19 vaccine and BNT162b2 vaccine for healthcare workers in South Korea;Bae;J Kor Med Sci,2021
5. Comparison of medium-term adverse reactions induced by the first and second dose of mRNA BNT162b2 (Comirnaty, Pfizer-BioNTech) vaccine: a post-marketing Italian study conducted between 1 January and 28 February 2021;Ossato;Eur J Hosp Pharm,2021
Cited by 14 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Adverse events of COVID-19 vaccination during 2021–2022 suppressed by breakfast consumption and favorable sleeping habit among Japanese university students;Vaccine: X;2024-08
2. Evaluating perceived side effects of SARS-CoV2 mRNA vaccines by lifestyle factors and nutritional status: Perspectives from a pilot study;Journal of Agriculture and Food Research;2024-06
3. Modulation of innate immune response to mRNA vaccination after SARS-CoV-2 infection or sequential vaccination in humans;JCI Insight;2024-05-08
4. Interstitial Lung Disease With Respiratory Failure After COVID-19 mRNA Vaccination;Cureus;2024-04-17
5. A scoping review of active, participant centred, digital adverse events following immunization (AEFI) surveillance of WHO approved COVID-19 vaccines: A Canadian immunization Research Network study;Human Vaccines & Immunotherapeutics;2024-02-19
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3